{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Hodgkin%27s+Lymphoma&page=2", "query": { "condition": "Non-Hodgkin's Lymphoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Hodgkin%27s+Lymphoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-21T23:34:29.812Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00003269", "title": "Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Drug/Agent Toxicity by Tissue/Organ", "Lung Cancer", "Lymphoma", "Ovarian Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "amifostine trihydrate", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Scripps Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 20, "start_date": "1998-02", "completion_date": "2001-01", "has_results": false, "last_update_posted_date": "2011-01-10", "last_synced_at": "2026-05-21T23:34:29.812Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003269" }, { "nct_id": "NCT03677141", "title": "A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B-cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Mosunetuzumab", "type": "DRUG" }, { "name": "Polatuzumab Vedotin", "type": "DRUG" }, { "name": "Rituxumab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 117, "start_date": "2019-03-08", "completion_date": "2023-10-12", "has_results": true, "last_update_posted_date": "2024-12-18", "last_synced_at": "2026-05-21T23:34:29.812Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • La Jolla, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03677141" }, { "nct_id": "NCT00619645", "title": "Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "busulfan", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 8, "start_date": "2007-06", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2018-01-10", "last_synced_at": "2026-05-21T23:34:29.812Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00619645" }, { "nct_id": "NCT00898872", "title": "SWOG-9245 Collecting and Storing Tissue Samples From Patients With Relapsed or Recurrent Non-Hodgkin Lymphoma After Treatment on a Southwest Oncology Group Clinical Trial", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "cryopreservation", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "1993-03", "completion_date": "2011-07", "has_results": false, "last_update_posted_date": "2013-05-20", "last_synced_at": "2026-05-21T23:34:29.812Z", "location_count": 82, "location_summary": "Anchorage, Alaska • Atlanta, Georgia • Austell, Georgia + 51 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00898872" }, { "nct_id": "NCT00082654", "title": "Study of the Emotional Needs of Caregivers of Stem Cell Transplantation Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer", "Chronic Myeloproliferative Disorders", "Gestational Trophoblastic Tumor", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases", "Neuroblastoma", "Ovarian Cancer", "Psychosocial Effects of Cancer and Its Treatment", "Testicular Germ Cell Tumor" ], "interventions": [ { "name": "psychosocial assessment and care", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": null, "start_date": "2002-03", "completion_date": "2004-10", "has_results": false, "last_update_posted_date": "2010-09-21", "last_synced_at": "2026-05-21T23:34:29.812Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00082654" }, { "nct_id": "NCT02169505", "title": "Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Brentuximab Vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 2, "start_date": "2015-05-22", "completion_date": "2017-08-14", "has_results": true, "last_update_posted_date": "2019-11-27", "last_synced_at": "2026-05-21T23:34:29.812Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02169505" }, { "nct_id": "NCT01930162", "title": "Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Single Umbilical Cord Blood Transplantation", "Non-myeloablative Conditioning", "Acute Lymphocytic Leukemia", "Myelodysplastic Syndrome", "Non-Hodgkin's Lymphoma", "Multiple Myeloma", "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "HSC835", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 9, "start_date": "2014-10-07", "completion_date": "2016-08-29", "has_results": true, "last_update_posted_date": "2021-01-05", "last_synced_at": "2026-05-21T23:34:29.812Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01930162" }, { "nct_id": "NCT01995669", "title": "Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Grade 3a Follicular Lymphoma", "Recurrent Follicular Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Refractory Follicular Lymphoma", "Refractory Marginal Zone Lymphoma", "Refractory Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2014-05-27", "completion_date": "2023-01-23", "has_results": true, "last_update_posted_date": "2025-06-24", "last_synced_at": "2026-05-21T23:34:29.812Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01995669" }, { "nct_id": "NCT06357754", "title": "Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Non-Hodgkin Lymphoma", "Chronic Lymphocytic Leukaemia", "Multiple Myeloma" ], "interventions": [ { "name": "Idecabtagene vicleucel", "type": "BIOLOGICAL" }, { "name": "Lisocabtagene maraleucel", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 50, "start_date": "2023-10-06", "completion_date": "2038-10-06", "has_results": false, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-05-21T23:34:29.812Z", "location_count": 4, "location_summary": "Portland, Oregon • Dallas, Texas • Salt Lake City, Utah + 1 more", "locations": [ { "city": "Portland", "state": "Oregon" }, { "city": "Dallas", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT06357754" }, { "nct_id": "NCT04930653", "title": "Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Folliculotropic Mycosis Fungoides", "Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Sezary Syndrome", "Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8", "Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8", "Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8", "Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8", "Transformed Mycosis Fungoides" ], "interventions": [ { "name": "Extracorporeal Photopheresis", "type": "PROCEDURE" }, { "name": "Mogamulizumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2022-10-19", "completion_date": "2028-06-15", "has_results": false, "last_update_posted_date": "2025-10-14", "last_synced_at": "2026-05-21T23:34:29.812Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Duarte, California • Atlanta, Georgia", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04930653" } ] }